Iovance Biotherapeutics Inc Share Price Nasdaq
Equities
US53619R1023
Biotechnology & Medical Research
Sales 2024 * | 153M 12.05B | Sales 2025 * | 428M 33.76B | Capitalization | 2.99B 236B |
---|---|---|---|---|---|
Net income 2024 * | -356M -28.08B | Net income 2025 * | -199M -15.7B | EV / Sales 2024 * | 19.1 x |
Net cash position 2024 * | 72.44M 5.71B | Net cash position 2025 * | 144M 11.37B | EV / Sales 2025 * | 6.64 x |
P/E ratio 2024 * |
-8.18
x | P/E ratio 2025 * |
-15.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.59% |
Latest transcript on Iovance Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 29/09/16 |
Director of Finance/CFO | 51 | 13/12/20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 19/07/11 |
Director/Board Member | 56 | 06/06/16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 14/03/18 |
1st Jan change | Capi. | |
---|---|---|
-4.81% | 3.15B | |
-14.73% | 2.15B | |
-14.39% | 1.8B | |
+70.99% | 1.49B | |
+23.17% | 770M | |
-2.18% | 762M | |
-20.41% | 575M | |
+3.18% | 308M | |
+6.63% | 210M |